{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:16:51Z","timestamp":1790194611063,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017636","name":"Cancer Center Amsterdam","doi-asserted-by":"publisher","award":["PV 19\/02"],"award-info":[{"award-number":["PV 19\/02"]}],"id":[{"id":"10.13039\/501100017636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amsterdam UMC Young Talent Fund","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The response rate to immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) receptor is 13%\u201318% for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Detailed understanding of the tumor immune microenvironment (TIME) is crucial in order to explain and improve this response rate. HNSCCs arise at various anatomical locations including the oral cavity, hypopharynx, larynx and oropharynx. Studies directly comparing immune infiltration between anatomical sites are scarce. Since the distinct locations could drive deviating microenvironments, we questioned whether the immune composition varies across these HNSCC sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Here, we characterized the TIME of 76 fresh tumor specimens using flow cytometry and performed single-cell RNA-sequencing on nine head and neck tumor samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found major differences in the composition of the TIME between patients. When comparing anatomical sites: tumors originating from the oral cavity had higher T cell infiltrates than tumors from other anatomical sites. The percentage of tumor-infiltrating T-lymphocytes positive for the immune checkpoint PD-1 varied considerably between patients, with the highest fraction of PD-1+ T cells found in larynx squamous cell carcinomas (SCCs). While we had hypothesized that the anatomical sites of tumor origin would drive sample clustering, our data showed that the type of TIME was more dominant and was particularly driven by the fraction of T cells positive for PD-1. Moreover, a high proportion of PD-1+ CD8+ T cells associated with an improved overall survival. Using single-cell RNA-sequencing, we observed that PD-1 expression was highest in the CD8-ENTPD1 tissue resident memory T cell\/exhausted T cell and CD4-CXCL13 type 1 T helper cell clusters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found that oral cavity SCCs had the highest frequencies of T cells. We also observed considerable interpatient heterogeneity for PD-1 on T cells, with noticeably higher frequencies of PD-1+ CD4+ T helper cells in larynx SCCs. Within the entire cohort, a higher fraction of CD8+ T cells positive for PD-1 was linked to improved overall survival. Whether the fraction of PD-1+ T cells within the TIME enables immune checkpoint inhibitor response prediction for patients with head and neck cancer remains to be determined.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007573","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T21:56:14Z","timestamp":1705010174000},"page":"e007573","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-5694","authenticated-orcid":false,"given":"Tara","family":"Muijlwijk","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis N L M","family":"Nijenhuis","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja H","family":"Ganzevles","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen","family":"Brink","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N","family":"Fass","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Earle A Chiles Research Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rajamanickam","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Earle A Chiles Research Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Ren\u00e9","family":"Leemans","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Koguchi","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Earle A Chiles Research Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-5947","authenticated-orcid":false,"given":"Bernard A","family":"Fox","sequence":"additional","affiliation":[{"name":"Providence Cancer Institute, Earle A Chiles Research Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos B","family":"Poell","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud H","family":"Brakenhoff","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4230-8383","authenticated-orcid":false,"given":"Rieneke","family":"van de Ven","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\/Head and Neck Surgery, Amsterdam UMC Location VUmc, Amsterdam, The Netherlands"},{"name":"Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"Cancer Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"2025100303050253000_12.1.e007573.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2025100303050253000_12.1.e007573.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"2025100303050253000_12.1.e007573.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2025100303050253000_12.1.e007573.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"2025100303050253000_12.1.e007573.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and Ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"2025100303050253000_12.1.e007573.6","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100303050253000_12.1.e007573.7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100303050253000_12.1.e007573.8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100303050253000_12.1.e007573.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2025100303050253000_12.1.e007573.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9"},{"key":"2025100303050253000_12.1.e007573.11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"key":"2025100303050253000_12.1.e007573.12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/jamaoto.2019.2427","article-title":"Prognostic value of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma","volume":"145","author":"Spector","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2025100303050253000_12.1.e007573.13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/jci.insight.93652","article-title":"Multiparametric immune profiling in HPV- oral squamous cell cancer","volume":"2","author":"Feng","year":"2017","journal-title":"JCI Insight"},{"key":"2025100303050253000_12.1.e007573.14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.celrep.2017.03.037","article-title":"Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis","volume":"19","author":"Tsujikawa","year":"2017","journal-title":"Cell Rep"},{"key":"2025100303050253000_12.1.e007573.15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1882743","article-title":"B-cell clusters at the invasive margin associate with longer survival in early-stage oral-tongue cancer patients","volume":"10","author":"Phanthunane","year":"2021","journal-title":"Oncoimmunology"},{"key":"2025100303050253000_12.1.e007573.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.11"},{"key":"2025100303050253000_12.1.e007573.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0227-z"},{"key":"2025100303050253000_12.1.e007573.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912217"},{"key":"2025100303050253000_12.1.e007573.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011"},{"key":"2025100303050253000_12.1.e007573.20","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00938-3","article-title":"The immune microenvironment in head and neck squamous cell carcinoma: on subsets and subsites","volume":"22","author":"Wondergem","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2025100303050253000_12.1.e007573.21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/hed.24406","article-title":"Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma","volume":"38","author":"Nguyen","year":"2016","journal-title":"Head Neck"},{"key":"2025100303050253000_12.1.e007573.22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89829","article-title":"The head and neck cancer immune landscape and its immunotherapeutic implications","volume":"1","author":"Mandal","year":"2016","journal-title":"JCI Insight"},{"key":"2025100303050253000_12.1.e007573.23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2018.02.005","article-title":"Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis","volume":"96","author":"Chen","year":"2018","journal-title":"Mol Immunol"},{"key":"2025100303050253000_12.1.e007573.24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1498439","article-title":"Treatment-naive HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy","volume":"7","author":"Gameiro","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100303050253000_12.1.e007573.25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1080\/0284186X.2018.1445287","article-title":"Immune cell infiltration in head and neck squamous cell carcinoma and patient outcome: a retrospective study","volume":"57","author":"Schneider","year":"2018","journal-title":"Acta Oncol"},{"key":"2025100303050253000_12.1.e007573.26","doi-asserted-by":"crossref","first-page":"1535293","DOI":"10.1080\/2162402X.2018.1535293","article-title":"Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinoma","volume":"8","author":"Lechner","year":"2019","journal-title":"OncoImmunology"},{"key":"2025100303050253000_12.1.e007573.27","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819867354","article-title":"Role of oral microbiome signatures in diagnosis and prognosis of oral cancer","volume":"18","author":"Chattopadhyay","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"2025100303050253000_12.1.e007573.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.11.014"},{"key":"2025100303050253000_12.1.e007573.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.044"},{"key":"2025100303050253000_12.1.e007573.30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643298","article-title":"Immunomodulation of T helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane vitamin D signaling pathway","volume":"12","author":"Fraga","year":"2021","journal-title":"Front Immunol"},{"key":"2025100303050253000_12.1.e007573.31","doi-asserted-by":"crossref","first-page":"44418","DOI":"10.18632\/oncotarget.17901","article-title":"Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma","volume":"8","author":"Lechner","year":"2017","journal-title":"Oncotarget"},{"key":"2025100303050253000_12.1.e007573.32","doi-asserted-by":"crossref","first-page":"842153","DOI":"10.3389\/fcell.2022.842153","article-title":"Lactobacillus suppresses tumorigenesis of oropharyngeal cancer via enhancing anti-tumor immune response","volume":"10","author":"Wang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"2025100303050253000_12.1.e007573.33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3556"},{"key":"2025100303050253000_12.1.e007573.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.06.018"},{"key":"2025100303050253000_12.1.e007573.35","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87324"},{"key":"2025100303050253000_12.1.e007573.36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100303050253000_12.1.e007573.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2606"},{"key":"2025100303050253000_12.1.e007573.38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hed.26498","article-title":"Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma","volume":"43","author":"Kikuchi","year":"2021","journal-title":"Head Neck"},{"key":"2025100303050253000_12.1.e007573.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.132"},{"key":"2025100303050253000_12.1.e007573.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0057-z"},{"key":"2025100303050253000_12.1.e007573.41","doi-asserted-by":"crossref","first-page":"101480","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin Immunol"},{"key":"2025100303050253000_12.1.e007573.42","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of Cd39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"2025100303050253000_12.1.e007573.43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI156821","article-title":"PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors","volume":"132","author":"Duhen","year":"2022","journal-title":"J Clin Invest"},{"key":"2025100303050253000_12.1.e007573.44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-110519-071134"},{"key":"2025100303050253000_12.1.e007573.45","doi-asserted-by":"crossref","unstructured":"Li JP , Wu CY , Chen MY , et al . PD-1(+)CXCR5(-)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer 2021;9. doi:10.1136\/jitc-2020-002101","DOI":"10.1136\/jitc-2020-002101"},{"key":"2025100303050253000_12.1.e007573.46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061524"},{"key":"2025100303050253000_12.1.e007573.47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","article-title":"A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers","volume":"40","author":"Hanada","year":"2022","journal-title":"Cancer Cell"},{"key":"2025100303050253000_12.1.e007573.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.002"},{"key":"2025100303050253000_12.1.e007573.49","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8"},{"key":"2025100303050253000_12.1.e007573.50","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1126\/scitranslmed.abc4220","article-title":"ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC","volume":"12","author":"Goswami","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007573","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:05:13Z","timestamp":1759485913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/jitc-2023-007573"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007573","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}